Cancer immunotherapy vaccine
This page covers all Cancer immunotherapy vaccine drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Tumor-associated antigens (pancreatic cancer cell surface antigens); PD-1/PD-L1 pathway.
Targets
Tumor-associated antigens (pancreatic cancer cell surface antigens); PD-1/PD-L1 pathway
Marketed (1)
- LI · CEL-SCI Corporation · Oncology
LI is an immunotherapeutic agent designed to enhance immune response against cancer cells.
Phase 3 pipeline (3)
- AScVS + Prazosin · Haffkine Bio-Pharmaceutical Corporation Ltd. · Oncology
AScVS is an autologous stem cell vaccine that stimulates immune responses against cancer, combined with prazosin, an alpha-1 adrenergic antagonist that may enhance immune function. - HyperAcute-Pancreas Immunotherapy · NewLink Genetics Corporation · Oncology
HyperAcute-Pancreas is an immunotherapy that activates the patient's immune system to recognize and attack pancreatic cancer cells by combining a tumor-associated antigen vaccine with an immune checkpoint inhibitor. - IMM-101 · Immodulon Therapeutics Ltd · Oncology
IMM-101 is an immunotherapeutic vaccine that activates the immune system against Mycobacterium obuense to enhance anti-tumor immunity.
Phase 1 pipeline (1)
- APVAC2 vaccine plus Poly-ICLC and GM-CSF · Immatics Biotechnologies GmbH · Oncology
APVAC2 vaccine plus Poly-ICLC and GM-CSF is a cancer immunotherapy that targets tumor cells by stimulating the immune system through activation of dendritic cells and subsequent activation of T cells.
Patent intelligence
- cancer immunotherapy patent landscape — aggregated cliff calendar, attackable patents, originator estates